Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract reviews the unclear link between androgenic alopecia and prostate cancer, highlighting the need for further research to determine the mechanisms connecting these two conditions.

In laboratory tests, this study found that a novel natural composition targeting 5-alpha reductase and inflammatory pathways reduced disease-related markers in androgenetic alopecia and benign prostatic hyperplasia more effectively than finasteride.

This literature review identified that phosphodiesterase 5 inhibitors, such as Tadalafil, are highly effective in improving lower urinary tract symptoms associated with benign prostatic hyperplasia, while the efficacy of saw palmetto remains inconsistent.

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

This review discusses the role of 5α-reductase in prostate development and BPH, and reports no new clinical results; ongoing trials are exploring dual isozyme inhibitors for improved treatment efficacy.

This review critically examines the current medical management strategies for BPH/LUTS and reports no new experimental results.

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

This review discusses phytotherapy options for managing benign prostatic hyperplasia, noting some herbal agents show promise in trials for mild-moderate symptoms but more evidence is needed for others.

This study found that 5α-reductase inhibitors significantly increase the risk of erectile dysfunction and hypoactive sexual desire in men with benign prostatic hyperplasia, compared to placebo.

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.

This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.

This review summarized existing research on finasteride and erectile dysfunction, finding a correlation between finasteride use for benign prostatic hyperplasia and ED, but not strongly for male androgenetic alopecia.

This study found that long-term finasteride therapy in men with BPH worsened erectile dysfunction and reduced testosterone levels, while these effects were not observed with tamsulosin.

This study found that low doses of bisphenol A may increase proliferation of the ventral prostate in adult rats by altering the estrogen to androgen ratio and gene expression.

In a rat model of benign prostatic hyperplasia, this study found that purple corn extract may improve symptoms by inhibiting prostate enlargement, reducing androgen receptor signaling, and exerting anti-inflammatory effects.

This cohort study using real-world data found no significant difference in the risk of developing prostate cancer between finasteride and dutasteride among patients with benign prostatic hyperplasia, despite previous suggestions that dutasteride might be more effective.

This study found that high-dose pterostilbene potentially reduced prostate hyperplasia and had strong antioxidant effects in male rats with benign prostatic hyperplasia, suggesting it might be more effective than vitamin C and resveratrol in similar contexts.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

This review details contemporary medical management options for benign prostatic hyperplasia, highlighting the expanding role of phosphodiesterase-5 inhibitors and beta-3 agonists, but reports no new clinical findings.

The researchers reported that finasteride was effective in controlling hormone-related dysfunction in an adult dog diagnosed with benign prostatic hyperplasia, although the condition regressed after the medication was withdrawn.

Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.

This study found that dutasteride is more cost-effective compared to finasteride for treating benign prostatic hyperplasia in Montenegro, justifying its funding by the national health insurance fund.

Serum triglyceride levels are not linked to prostate cancer risk.

This study examined serum PSA levels in women with androgenetic alopecia to evaluate their potential as a marker for androgen effects on target organs.

In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.

This study suggests that finasteride may reduce the aggressiveness and invasion of prostate tumors, with effects potentially differing based on the androgen responsiveness of the patient's prostate cells.

This review discusses how the HSD3B1(1245C) genotype may impact androgen physiology and the progression of castration-resistant prostate cancer, and does not report new experimental results.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.

In this study, low dose finasteride or dutasteride treatment was found to reduce prostate specific antigen levels in men with androgenetic alopecia, though levels sometimes remained stable or increased in those with low baseline PSA.